Clinical Trials | June 14, 2024
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
This strategic decision will unlock significant value for our scientific and industrial products business
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
